In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy-Reference-Cited by-同舟云学术

In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy

Published:2022-05-03 Issue:11 Volume:49 Page:3841-3851
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Syguła Aleksandra,Ledwon Aleksandra,Hasse-Lazar Kornelia,Jurecka-Lubieniecka Beata,Michalik Barbara,Paliczka-Cieślik Ewa,Zeman Marcin,Chmielik Ewa,Sczasny Joanna,Jarzab Barbara,Handkiewicz-Junak Daria^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00259-022-05792-y.pdf

Reference51 articles.

1. Reubi JC. Peptide receptor expression in GEP-NET [eng]. Virchows Arch. 2007;451 Suppl 1:S47–S50. https://doi.org/10.1007/s00428-007-0443-2.

2. Ahlman H, Wängberg B, Nilsson O, Grimelius L, Granérus G, Modlin IM, et al. Aspects on diagnosis and treatment of the foregut carcinoid syndrome [eng]. Scand J Gastroenterol. 1992;27:59–71. https://doi.org/10.3109/00365529209000106.

3. Oberg K, Ferone D, Kaltsas G, Knigge U-P, Taal B, Plöckinger U. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biotherapy [eng]. Neuroendocrinology. 2009;90:09–213. https://doi.org/10.1159/000183751.

4. Schally AV. Oncological applications of somatostatin analogues [eng]. Cancer Res. 1988;48(24 Pt 1):6977–85.

5. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB. The somatostatin receptor family [eng]. Life Sci. 1995;57:9–65. https://doi.org/10.1016/0024-3205(95)02082-t.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sequencing of Somatostatin-Receptor–Based Therapies in Neuroendocrine Tumor Patients;Journal of Nuclear Medicine;2024-01-18

2. From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms;Therapeutic Advances in Medical Oncology;2024-01

3. The Robustness Index: Going Beyond Statistical Significance by Quantifying Fragility;Cureus;2023-08-30

4. Targeting neuroendocrine tumors with octreotide and lanreotide: Key points for clinical practice from NET specialists;Cancer Treatment Reviews;2023-06

5. A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients;Cancers;2022-11-24